We have located links that may give you full text access.
False-Positive Rates, Risk Factors, and Interpretations of the Vestibular Ocular Motor Screen in Collegiate Athletes.
Journal of Athletic Training 2023 November 29
CONTEXT: Biological sex and history of motion sickness are known modifiers associated with a false-positive baseline Vestibular Ocular Motor Screen (VOMS). However, other factors may associate with a false-positive VOMS in collegiate athletes.
OBJECTIVE: Identify contributing factors to false-positive VOMS assessments using population specific criteria. We also critically appraised previously reported interpretation criterion.
DESIGN: Descriptive Laboratory.
SETTING: Single site collegiate athletic training clinic.
PATIENTS OR OTHER PARTICIPANTS: NCAA Division 1 athletes (n=462[41% female]) who were 18.8±1.4 years old.
MAIN OUTCOME MEASURES: Participants completed the Athlete Sleep Behavior Questionnaire (ASBQ), Generalized Anxiety Index (GAD-7), the ImPACT battery, Patient Health Questionnaire (PHQ-9), Revised Head Injury Scale (HIS-r), the Sensory Organization Test (SOT), and the VOMS as part of a multidimensional baseline concussion assessment. Participants were classified into two groups based on whether they had a total symptom score of ≥8 following VOMS administration, excluding the baseline checklist. Chi-squared (χ2) and independent t-tests compared group demographics. A binary logistic regression with adjusted odds ratios (OR) evaluated the influence of sex, corrected vision, ADHD, ImPACT composite scores, concussion history, a history of treatment for headache and/or migraine, GAD-7, PHQ-9, ASBQ, and SOT Equilibrium Score, and Somatosensory, Visual, and Vestibular sensory ratios on false-positive rates.
RESULTS: Approximately 9.1% (42/462 [30 females]) met criteria for a false-positive VOMS. A significantly greater proportion of females had false-positives (χ2(1) = 18.37, p < 0.001). Female sex (OR=2.79, 95% CI [1.17-6.65], p =.02) and history of treatment for headache (OR=4.99, 95% CI [1.21-20.59], p=0.026) were the only significant predictors of false-positive VOMS. Depending on cutoff interpretation, false-positive rates using our data ranged from 9.1%-22.5%.
CONCLUSIONS: Our results support the most recent interpretation guidelines for the VOMS in collegiate athletes due to a low false-positive rate and ease of interpretation. Biological sex and history of headaches should be considered when administering the VOMS in the absence of a baseline.
OBJECTIVE: Identify contributing factors to false-positive VOMS assessments using population specific criteria. We also critically appraised previously reported interpretation criterion.
DESIGN: Descriptive Laboratory.
SETTING: Single site collegiate athletic training clinic.
PATIENTS OR OTHER PARTICIPANTS: NCAA Division 1 athletes (n=462[41% female]) who were 18.8±1.4 years old.
MAIN OUTCOME MEASURES: Participants completed the Athlete Sleep Behavior Questionnaire (ASBQ), Generalized Anxiety Index (GAD-7), the ImPACT battery, Patient Health Questionnaire (PHQ-9), Revised Head Injury Scale (HIS-r), the Sensory Organization Test (SOT), and the VOMS as part of a multidimensional baseline concussion assessment. Participants were classified into two groups based on whether they had a total symptom score of ≥8 following VOMS administration, excluding the baseline checklist. Chi-squared (χ2) and independent t-tests compared group demographics. A binary logistic regression with adjusted odds ratios (OR) evaluated the influence of sex, corrected vision, ADHD, ImPACT composite scores, concussion history, a history of treatment for headache and/or migraine, GAD-7, PHQ-9, ASBQ, and SOT Equilibrium Score, and Somatosensory, Visual, and Vestibular sensory ratios on false-positive rates.
RESULTS: Approximately 9.1% (42/462 [30 females]) met criteria for a false-positive VOMS. A significantly greater proportion of females had false-positives (χ2(1) = 18.37, p < 0.001). Female sex (OR=2.79, 95% CI [1.17-6.65], p =.02) and history of treatment for headache (OR=4.99, 95% CI [1.21-20.59], p=0.026) were the only significant predictors of false-positive VOMS. Depending on cutoff interpretation, false-positive rates using our data ranged from 9.1%-22.5%.
CONCLUSIONS: Our results support the most recent interpretation guidelines for the VOMS in collegiate athletes due to a low false-positive rate and ease of interpretation. Biological sex and history of headaches should be considered when administering the VOMS in the absence of a baseline.
Full text links
Related Resources
Trending Papers
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Ventilator Waveforms May Give Clues to Expiratory Muscle Activity.American Journal of Respiratory and Critical Care Medicine 2024 April 25
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.Pharmaceuticals 2024 March 27
Systemic lupus erythematosus.Lancet 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app